T細胞受體 (TCR) 為基礎的抗體及T細胞免疫療法:報告2冊套組
2 Reports Bundle: TCR-Based Antibody and T-Cell Immunotherapy
|出版商||La Merie Publishing||商品編碼||651128|
|T細胞受體 (TCR) 為基礎的抗體及T細胞免疫療法:報告2冊套組 2 Reports Bundle: TCR-Based Antibody and T-Cell Immunotherapy|
|出版日期: 2018年05月31日||內容資訊: 英文||
本報告套組，由TCR-T細胞及重組抗體 (融合蛋白質) 的癌症的免疫療法相關2冊的報告所構成，提供市場背景，主要技術、主要產品、主要企業的簡介，開發平台趨勢，事業開發、資金籌措、企業間的主要契約等趨勢。
T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics. Both treatment modalities have in common that they are directed to intracellular targets wich are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies.
This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.
The original reports were published in January and May 2018, respectively:
Detailed report descriptions, tables of contents and sample pages from the reports can be found on the respective product page.